239 related articles for article (PubMed ID: 30385093)
1. Ductal Carcinoma in Situ Biomarkers in a Precision Medicine Era: Current and Future Molecular-Based Testing.
Shee K; Muller KE; Marotti J; Miller TW; Wells WA; Tsongalis GJ
Am J Pathol; 2019 May; 189(5):956-965. PubMed ID: 30385093
[TBL] [Abstract][Full Text] [Related]
2. Molecular Evaluation of Breast Ductal Carcinoma in Situ with Oncotype DX DCIS.
Nofech-Mozes S; Hanna W; Rakovitch E
Am J Pathol; 2019 May; 189(5):975-980. PubMed ID: 30605628
[TBL] [Abstract][Full Text] [Related]
3. Can Molecular Biomarkers Help Reduce the Overtreatment of DCIS?
Hahn E; Rodin D; Sutradhar R; Nofech-Mozes S; Trebinjac S; Paszat LF; Rakovitch E
Curr Oncol; 2023 Jun; 30(6):5795-5806. PubMed ID: 37366916
[TBL] [Abstract][Full Text] [Related]
4. Functional Role of miRNAs in the Progression of Breast Ductal Carcinoma in Situ.
Hannafon BN; Ding WQ
Am J Pathol; 2019 May; 189(5):966-974. PubMed ID: 30273605
[TBL] [Abstract][Full Text] [Related]
5. Her2 and Ki67 Biomarkers Predict Recurrence of Ductal Carcinoma in Situ.
Davis JE; Nemesure B; Mehmood S; Nayi V; Burke S; Brzostek SR; Singh M
Appl Immunohistochem Mol Morphol; 2016 Jan; 24(1):20-5. PubMed ID: 26317313
[TBL] [Abstract][Full Text] [Related]
6. Qualitative Radiogenomics: Association Between BI-RADS Calcification Descriptors and Recurrence Risk as Assessed by the Oncotype DX Ductal Carcinoma In Situ Score.
Woodard GA; Price ER
AJR Am J Roentgenol; 2019 Apr; 212(4):919-924. PubMed ID: 30714832
[TBL] [Abstract][Full Text] [Related]
7. Validation of an oligo-gene signature for the prognostic stratification of ductal carcinoma in situ (DCIS).
Geradts J; Groth J; Wu Y; Jin G
Breast Cancer Res Treat; 2016 Jun; 157(3):447-59. PubMed ID: 27250000
[TBL] [Abstract][Full Text] [Related]
8. Clinicopathological Risk Factors for an Invasive Breast Cancer Recurrence after Ductal Carcinoma
Visser LL; Elshof LE; Schaapveld M; van de Vijver K; Groen EJ; Almekinders MM; Bierman C; van Leeuwen FE; Rutgers EJ; Schmidt MK; Lips EH; Wesseling J
Clin Cancer Res; 2018 Aug; 24(15):3593-3601. PubMed ID: 29685879
[No Abstract] [Full Text] [Related]
9. Leveraging the variable natural history of ductal carcinoma in situ (DCIS) to select optimal therapy.
Rojas KE; Fortes TA; Borgen PI
Breast Cancer Res Treat; 2019 Apr; 174(2):307-313. PubMed ID: 30536119
[TBL] [Abstract][Full Text] [Related]
10. The current clinical value of the DCIS Score.
Wood WC; Alvarado M; Buchholz DJ; Hyams D; Hwang S; Manders J; Park C; Solin LJ; White J; Willey S
Oncology (Williston Park); 2014 May; 28 Suppl 2():C2, 1-8, C3. PubMed ID: 25375000
[TBL] [Abstract][Full Text] [Related]
11. MiRNA expression deregulation correlates with the Oncotype DX
Loudig O; Mitchell MI; Ben-Dov IZ; Liu C; Fineberg S
Breast Cancer Res; 2022 Sep; 24(1):62. PubMed ID: 36096802
[TBL] [Abstract][Full Text] [Related]
12. Progression of ductal carcinoma in situ to invasive breast cancer: comparative genomic sequencing.
Doebar SC; Krol NM; van Marion R; Brouwer RWW; van Ijcken WFJ; Martens JM; Dinjens WNM; van Deurzen CHM
Virchows Arch; 2019 Feb; 474(2):247-251. PubMed ID: 30284611
[TBL] [Abstract][Full Text] [Related]
13. Ductal carcinoma in situ of the breast: the importance of morphologic and molecular interactions.
Mardekian SK; Bombonati A; Palazzo JP
Hum Pathol; 2016 Mar; 49():114-23. PubMed ID: 26826418
[TBL] [Abstract][Full Text] [Related]
14. Evaluating patterns of utilization of gene signature panels and impact on treatment patterns in patients with ductal carcinoma in situ of the breast.
Bhutiani N; Vuong B; Egger ME; Eldredge-Hindy H; McMasters KM; Ajkay N
Surgery; 2019 Oct; 166(4):509-514. PubMed ID: 31337506
[TBL] [Abstract][Full Text] [Related]
15. A breast one-patient panel of heterogeneous genomes reveals genetic alterations driving DCIS into invasive lesions.
Yang M; Xu Z; Zhang QZ; Wang K; Ji XY; Xu J; Zhang JY; Niu G
Future Oncol; 2019 May; 15(14):1565-1576. PubMed ID: 30888194
[No Abstract] [Full Text] [Related]
16. Current Approaches to Diagnosis and Treatment of Ductal Carcinoma In Situ and Future Directions.
Ryan R; Tawfik O; Jensen RA; Anant S
Prog Mol Biol Transl Sci; 2017; 151():33-80. PubMed ID: 29096897
[TBL] [Abstract][Full Text] [Related]
17. Comparison of HER2 amplification status among breast cancer subgroups offers new insights in pathways of breast cancer progression.
Lambein K; Van Bockstal M; Vandemaele L; Van den Broecke R; Cocquyt V; Geenen S; Denys H; Libbrecht L
Virchows Arch; 2017 Nov; 471(5):575-587. PubMed ID: 28567637
[TBL] [Abstract][Full Text] [Related]
18. Evidence that molecular changes in cells occur before morphological alterations during the progression of breast ductal carcinoma.
Castro NP; Osório CA; Torres C; Bastos EP; Mourão-Neto M; Soares FA; Brentani HP; Carraro DM
Breast Cancer Res; 2008; 10(5):R87. PubMed ID: 18928525
[TBL] [Abstract][Full Text] [Related]
19. Comparative effectiveness of incorporating a hypothetical DCIS prognostic marker into breast cancer screening.
Trentham-Dietz A; Ergun MA; Alagoz O; Stout NK; Gangnon RE; Hampton JM; Dittus K; James TA; Vacek PM; Herschorn SD; Burnside ES; Tosteson ANA; Weaver DL; Sprague BL
Breast Cancer Res Treat; 2018 Feb; 168(1):229-239. PubMed ID: 29185118
[TBL] [Abstract][Full Text] [Related]
20. Will oncotype DX DCIS testing guide therapy? A single-institution correlation of oncotype DX DCIS results with histopathologic findings and clinical management decisions.
Lin CY; Mooney K; Choy W; Yang SR; Barry-Holson K; Horst K; Wapnir I; Allison K
Mod Pathol; 2018 Apr; 31(4):562-568. PubMed ID: 29243740
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
